Valeant Pharmaceuticals' Debt Reduction Overshadows Drop in Revenue
One major question Valeant Pharmaceuticals (NYSE: VRX) had to answer when the company reported its second-quarter results was this: How significant was the impact of loss of exclusivity for several of its drugs? The drugmaker raised its full-year 2017 guidance three months ago, banking on that impact being less than initially feared.
Valeant answered this question when the company reported on its second-quarter performance before the market opened on Tuesday. The bigger story, though, related to its debt-reduction efforts. Here are the highlights from Valeant's update.
Image source: Getty Images.
Source: Fool.com
Bausch Health Companies Inc. Aktie
6,00 €
-3,05 %
Bausch Health Companies Inc. erfreut sich mäßiger Beliebtheit, mit mehr Buy- als Sell-Einschätzungen.
Mit einem Kursziel von 16 € für Bausch Health Companies Inc. zeigt sich ein beachtliches Wachstumspotenzial gegenüber dem aktuellen Kurs von 6.0 €.
